Valneva SE (XPAR:VLA)
€ 3.872 0.062 (1.63%) Market Cap: 538.80 Mil Enterprise Value: 573.83 Mil PE Ratio: 0 PB Ratio: 2.85 GF Score: 64/100

Valneva SE at Jefferies Healthcare Conference Transcript

Jun 07, 2023 - Jun 09, 2023 / NTS GMT
Release Date Price: €5.82 (-2.41%)
Maury Raycroft
Jefferies LLC - Analyst

My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. So it's great pleasure that I'd like to welcome Peter Bühler, the CFO of Valneva. Valneva has a lot going on with their clinical programs, filing for chikungunya and also with the commercial portfolio as well. And so without further ado, I'm going to turn it over to Peter to tell you more about the company. Thanks for joining us, Peter.

Peter Bühler
Valneva SE - CFO

Thank you, Maury, and good afternoon, everyone. As usual, we have a forward-looking statement here. I will skip that.

So Valneva, we are a fully integrated specialty vaccine company. And we're basically focusing on prophylactic vaccines. We develop, manufacture, and commercialize those. And we're really focusing on vaccines for infectious diseases with high unmet medical need.

What we're typically targeting is vaccines that are either first in class, best in class, or only in class. So we are highly specialized and targeted in our development. And we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot